Literature DB >> 15347849

Differences in airway remodeling between asthma and chronic obstructive pulmonary disease.

Kazutetsu Aoshiba1, Atsushi Nagai.   

Abstract

The functional consequence of asthma and chronic obstructive pulmonary disease (COPD)is airflow limitation, which is mostly reversible in asthma and not fully reversible in COPD. In both diseases, inflammatory conditions are associated with cellular and structural changes,referred to as remodeling, and these structural changes may lead to thickening of the airway wall, thereby promoting airway narrowing and airflow limitation. However, the pattern of infiltrated cells and the pattern of structural changes occur differently in the two diseases. In asthma, CD4+, T lymphocytes, eosinophils, and mast cells are the predominant cells involved,whereas in COPD, CD8+, T lymphocytes, and macrophages are predominantly involved. In severe cases of asthma and COPD, neutrophil infiltration becomes evident. Regarding structural changes, epithelial injury and early thickening of reticular basement membrane are highly characteristic of the airway wall of asthmatics. Increases in airway smooth muscle mass occur in large airways of severe asthmatics and in small airways of patients with COPD. Thickening of the airway wall, goblet cell hyperplasia, mucous gland hypertrophy, and the luminal obstruction caused by inflammatory exudates and mucous are features of both asthma and COPD. Squamous epithelial metaplasia and airway wall fibrosis are commonly observed characteristics of COPD. Destruction and fibrosis of the alveolar wall occur in COPD but not in asthma. The remodeling processes accompanied by chronic inflammatory infiltrates interact in a complex fashion and contribute to the development of airflow limitation in both asthma and COPD.

Entities:  

Mesh:

Year:  2004        PMID: 15347849     DOI: 10.1385/CRIAI:27:1:035

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  64 in total

1.  Airway structural alterations selectively associated with severe asthma.

Authors:  Laurent Benayoun; Anne Druilhe; Marie-Christine Dombret; Michel Aubier; Marina Pretolani
Journal:  Am J Respir Crit Care Med       Date:  2003-01-16       Impact factor: 21.405

2.  Quantifying proliferation of cultured human and rabbit airway smooth muscle cells in response to serum and platelet-derived growth factor.

Authors:  S J Hirst; P J Barnes; C H Twort
Journal:  Am J Respir Cell Mol Biol       Date:  1992-12       Impact factor: 6.914

3.  Inflammatory cell distribution within and along asthmatic airways.

Authors:  K J Haley; M E Sunday; B R Wiggs; H P Kozakewich; J J Reilly; S J Mentzer; D J Sugarbaker; C M Doerschuk; J M Drazen
Journal:  Am J Respir Crit Care Med       Date:  1998-08       Impact factor: 21.405

4.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids.

Authors:  S E Wenzel; S J Szefler; D Y Leung; S I Sloan; M D Rex; R J Martin
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

5.  Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters.

Authors:  A B Thompson; D Daughton; R A Robbins; M A Ghafouri; M Oehlerking; S I Rennard
Journal:  Am Rev Respir Dis       Date:  1989-12

6.  Epidermal growth factor system regulates mucin production in airways.

Authors:  K Takeyama; K Dabbagh; H M Lee; C Agustí; J A Lausier; I F Ueki; K M Grattan; J A Nadel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

7.  Ongoing airway inflammation in patients with COPD who do not currently smoke.

Authors:  S R Rutgers; D S Postma; N H ten Hacken; H F Kauffman; T W van Der Mark; G H Koëter; W Timens
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

8.  Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease.

Authors:  W I de Boer; A van Schadewijk; J K Sont; H S Sharma; J Stolk; P S Hiemstra; J H van Krieken
Journal:  Am J Respir Crit Care Med       Date:  1998-12       Impact factor: 21.405

9.  Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease.

Authors:  Yusheng Qiu; Jie Zhu; Venkata Bandi; Robert L Atmar; Keith Hattotuwa; Kay K Guntupalli; Peter K Jeffery
Journal:  Am J Respir Crit Care Med       Date:  2003-07-11       Impact factor: 21.405

10.  Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness.

Authors:  U A Temann; G P Geba; J A Rankin; R A Flavell
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

View more
  33 in total

Review 1.  State of the art. Apoptosis and cell homeostasis in chronic obstructive pulmonary disease.

Authors:  Peter M Henson; Gregory P Cosgrove; R William Vandivier
Journal:  Proc Am Thorac Soc       Date:  2006-08

2.  Leukocyte elastase induces lung epithelial apoptosis via a PAR-1-, NF-kappaB-, and p53-dependent pathway.

Authors:  Tomoko Suzuki; Cory Yamashita; Rachel L Zemans; Natalie Briones; Annemie Van Linden; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-23       Impact factor: 6.914

Review 3.  A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.

Authors:  M A Giembycz; M Kaur; R Leigh; R Newton
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

Review 4.  Cell death, remodeling, and repair in chronic obstructive pulmonary disease?

Authors:  Peter M Henson; R William Vandivier; Ivor S Douglas
Journal:  Proc Am Thorac Soc       Date:  2006-11

5.  Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype.

Authors:  Lennart K A Lundblad; John Thompson-Figueroa; Timothy Leclair; Michael J Sullivan; Matthew E Poynter; Charles G Irvin; Jason H T Bates
Journal:  Am J Respir Crit Care Med       Date:  2005-04-01       Impact factor: 21.405

6.  Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.

Authors:  Priya Muralidharan; Don Hayes; Stephen M Black; Heidi M Mansour
Journal:  Mol Syst Des Eng       Date:  2016-01-27

Review 7.  TGF-β1 Signaling and Tissue Fibrosis.

Authors:  Kevin K Kim; Dean Sheppard; Harold A Chapman
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

8.  Matrix Metalloproteinase-9 (279R/Q) Polymorphism is Associated with Clinical Severity and Airflow Limitation in Tunisian Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Sarra Bchir; Hela Ben Nasr; Imen Rekik Hakim; Amel Ben Anes; Saloua Yacoub; Abdelhamid Garrouch; Mohamed Benzarti; Brigitte Bauvois; Zouhair Tabka; Karim Chahed
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

9.  Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

Authors:  Jens Markus Borghardt; Benjamin Weber; Alexander Staab; Christina Kunz; Charlotte Kloft
Journal:  Br J Clin Pharmacol       Date:  2016-06-23       Impact factor: 4.335

Review 10.  Mouse models to unravel the role of inhaled pollutants on allergic sensitization and airway inflammation.

Authors:  Tania Maes; Sharen Provoost; Ellen A Lanckacker; Didier D Cataldo; Jeroen A J Vanoirbeek; Benoit Nemery; Kurt G Tournoy; Guy F Joos
Journal:  Respir Res       Date:  2010-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.